Gene therapy companies Verve, Intellia, and Regeneron are advancing development through collaborations and regulatory filings.
6 reports, 2 independent
Updated Sun 00:00
No new developments lately
- Reports
- 6
- Developments
- 3
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Gene therapy companies Verve, Intellia, and Regeneron are advancing development through collaborations and regulatory filings.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Intellia presented Phase 3 results for lonvo-z and is seeking FDA approval.1 source
- Companies are advancing gene therapy development and planning regulatory submissions.
- Intellia's Lonvo-z received a Market Perform rating from Citizens JMP for its HAE indication.
Keep exploring
The entities involved
-
Verve Therapeutics
American pharmaceutical company
Nothing else this week.
-
Intellia Therapeutics
It is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system.
Nothing else this week.
-
Regeneron Pharmaceuticals
American pharmaceutical company